Does Humana Cover Praluent (Alirocumab)? Coverage, Prior Auth & Appeals Explained

What Is Praluent and Why Does Coverage Complexity Exist?

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors on liver cells. By inhibiting PCSK9, the drug keeps more LDL receptors available on the hepatocyte surface, which drops circulating LDL-C by roughly 50 to 60 percent on top of statin therapy. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical ASCVD who need additional LDL lowering beyond maximally tolerated statin therapy [1].

The cost explains the coverage friction. At a list price near $580 per month, a one-year supply costs approximately $6,960 before rebates. Payers respond with prior authorization, step therapy, and LDL thresholds to limit spending to patients most likely to derive clinical benefit. The ACC/AHA 2018 Cholesterol Guideline specifically identifies PCSK9 inhibitors as appropriate for very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL despite maximally tolerated statin plus ezetimibe [2].

Coverage rules differ between Humana commercial plans and Humana Medicare Advantage plans because CMS sets different rules for each product line. Patients who understand both sets of criteria before the prescribing visit are better positioned to avoid outright denial.

Humana Commercial Plan Coverage for Praluent

Most Humana commercial (employer-sponsored and individual-market) plans place Praluent on tier 4 or tier 5, the specialty-drug tiers. That tier placement means member cost-sharing is typically 25 to 33 percent coinsurance or a fixed copay in the $100 to $200 per fill range, depending on the specific plan design. The pharmacy benefit may route the prescription to a specialty pharmacy rather than a retail chain.

Humana's commercial prior-authorization criteria generally require all of the following:

1. A documented diagnosis of HeFH, homozygous FH, or established ASCVD (defined as prior MI, stroke, or symptomatic peripheral artery disease).
2. A fasting LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for FH without prior ASCVD) measured while on maximally tolerated statin therapy.
3. A trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days, documented in the medical record.
4. A trial of ezetimibe 10 mg for at least 90 days, unless contraindicated or not tolerated.
5. Prescriber attestation that the prescribing clinician is a cardiologist, lipidologist, or endocrinologist, or that the patient was evaluated by one.

Documentation of statin intolerance requires at least two separate statin trials at different doses or with different statin molecules, each causing documented myalgia or elevated CK, per most commercial plan criteria aligned with the ACC Expert Consensus Decision Pathway on Statin Intolerance [3].

Approvals on commercial plans typically cover a 12-month period with annual reauthorization. Lab values must be re-submitted at reauthorization confirming ongoing LDL elevation or documented intolerance to alternatives.

Humana Medicare Advantage Coverage for Praluent

Medicare Advantage coverage is plan-specific and considerably more variable. CMS does not mandate PCSK9 inhibitor coverage, so individual MA contracts establish their own formularies. Several Humana MA plans in 2024 and 2025 listed alirocumab on Part D specialty tiers with prior authorization, while others placed it in a non-formulary status requiring a formulary exception [4].

The National Coverage Determination framework does not include a specific NCD for PCSK9 inhibitors, meaning each plan can apply its own medical-necessity standards. Humana MA prior-authorization criteria for alirocumab tend to be stricter than commercial criteria. Common MA-specific requirements include:

• LDL-C documentation while on maximally tolerated statin AND ezetimibe (not one or the other).
• Specialist involvement: a cardiology or endocrinology note within the prior 12 months.
• LDL threshold at or above 100 mg/dL for ASCVD and at or above 130 mg/dL for FH-only indication.
• Denial of the competing PCSK9 inhibitor evolocumab (Repatha) does not automatically apply; each drug is reviewed independently.

Medicare patients should confirm the exact formulary position on the CMS Plan Finder tool at medicare.gov before assuming coverage, because formularies change annually on January 1.

The ODYSSEY OUTCOMES Trial: Why Alirocumab Earned Its Place in Guidelines

Insurers who deny PCSK9 inhibitors on cost grounds face a strong evidence record from ODYSSEY OUTCOMES, a randomized, double-blind, placebo-controlled trial conducted at 1,315 sites in 57 countries [5]. The trial enrolled 18,924 patients who had experienced an acute coronary syndrome within 1 to 12 months and had LDL-C above 70 mg/dL on high-intensity statin therapy.

At a median follow-up of 2.8 years, alirocumab 75 to 150 mg every two weeks reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [5]. The absolute risk reduction was 1.6 percentage points, translating to a number needed to treat of 63 over 2.8 years. All-cause mortality was numerically lower with alirocumab (3.5 percent vs. 4.1 percent; HR 0.85; P=0.026), a finding that strengthened the drug's clinical profile compared with earlier PCSK9 trials [5].

The ACC/AHA 2018 Cholesterol Guideline states: "In very-high-risk patients, if the LDL-C level remains above 70 mg/dL while receiving maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable (Class IIa, LOE A)" [2]. That specific language is what prescribers should quote verbatim when submitting a letter of medical necessity to Humana.

Mean LDL-C reduction from baseline in ODYSSEY OUTCOMES was 54.7 percent at 12 months in the alirocumab group compared with 0.8 percent in the placebo group [5]. Injection-site reactions occurred in 3.8 percent of alirocumab patients vs. 2.1 percent of placebo patients, and neurocognitive events were numerically balanced between groups.

Step Therapy Requirements on Humana Plans

Humana applies step therapy to alirocumab on virtually all plan types. Step therapy means the insurer requires documented failure of lower-cost alternatives before it will authorize the target drug. For alirocumab, the step sequence typically runs:

Step 1. High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days. If intolerant, documentation of two failed statin trials at different agents or doses.

Step 2. Ezetimibe 10 mg added to maximally tolerated statin for at least 90 days. The IMPROVE-IT trial (N=18,144) demonstrated that ezetimibe added to simvastatin 40 mg reduced the 7-year composite MACE rate from 34.7 percent to 32.7 percent (HR 0.936; P=0.016), establishing it as a required non-statin step [6].

Step 3. In some plans, a bile acid sequestrant (cholestyramine, colesevelam) or bempedoic acid (Nexletol) may be required as a third step, particularly in statin-intolerant patients. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced MACE by 13 percent relative to placebo (HR 0.87; P=0.004) in statin-intolerant patients, which some plans now cite as a step-therapy alternative [7].

The step-therapy clock starts when the pharmacy claim or medical record shows the date the step drug was first dispensed. Lab values obtained before the step drug was started are generally not accepted as evidence of step-therapy failure on the step drug.

A 2023 analysis published in JAMA Cardiology found that step-therapy policies delayed PCSK9 inhibitor access by a median of 6.3 months among commercially insured high-risk ASCVD patients, a delay associated with higher rates of recurrent MI during the waiting period [8]. That paper is worth including in an appeal letter.

How to Submit a Prior Authorization for Praluent to Humana

The prescribing clinician or their office staff initiates the PA. Humana accepts PA requests through its online provider portal, by fax, or through CoverMyMeds. The required documentation packet should include:

• A completed Humana PA form for specialty cardiovascular agents.
• Office notes documenting the qualifying diagnosis (ICD-10 codes: E78.01 for FH, I25.10 for ASCVD).
• Lipid panel results (within 90 days) showing LDL-C while on maximally tolerated statin plus ezetimibe.
• Pharmacy dispensing records or medication lists confirming the statin and ezetimibe trial dates and doses.
• A letter of medical necessity referencing ODYSSEY OUTCOMES and the ACC/AHA 2018 Class IIa guideline recommendation.
• Specialist notes if required by the specific plan.

Humana's standard commercial PA turnaround is 72 hours for non-urgent requests and 24 hours for urgent requests, per CMS and state insurance regulations. Medicare Advantage PA decisions must be rendered within 72 hours for standard requests and 24 hours for expedited requests under 42 CFR Part 422 [9].

Requesting an expedited PA is appropriate when the prescribing physician documents that a standard timeline could jeopardize the patient's health, for example in a recently discharged ACS patient meeting ODYSSEY OUTCOMES eligibility criteria.

What to Do When Humana Denies Praluent

Denial rates for PCSK9 inhibitors remain high across all payers. A 2020 analysis in Circulation reported that approximately 80 percent of initial PCSK9 inhibitor PA requests were denied, and approximately half of appealed denials were ultimately reversed [10]. Persistence through the appeals process materially improves the approval rate.

Step 1: Internal Appeal. File a Level 1 internal appeal within the timeframe on the denial notice (typically 60 to 180 days for commercial plans, 60 days for Medicare Advantage). Submit the same documentation as the original PA plus the JAMA Cardiology delay-of-care analysis [8] and a formal letter of medical necessity signed by the treating physician.

Step 2: External Review. If the internal appeal is denied, commercial plan members in most states can request an Independent Medical Review (IMR) or external review through the state insurance commissioner's office. Medicare Advantage members escalate to MAXIMUS Federal Services, the CMS-contracted Qualified Independent Contractor (QIC). MAXIMUS must issue a decision within 60 days for standard reviews or 72 hours for expedited reviews.

Step 3: ALJ Hearing. MA members whose claim amount exceeds $180 (2024 threshold) may request an Administrative Law Judge hearing if MAXIMUS upholds the denial. An ALJ hearing must be scheduled within 90 days of the request [9].

Physician peer-to-peer calls with Humana's medical director often resolve denials at the internal-appeal stage. The call should be requested within 48 hours of receiving the denial letter to keep the appeal timeline intact.

The HealthRX clinical team has developed a three-document bundle, hereafter the "Praluent Prior Auth Bundle," that combines the ODYSSEY OUTCOMES hazard-ratio data, the ACC/AHA Class IIa language, and the JAMA Cardiology delay-of-care statistics into a single two-page letter of medical necessity. In an internal review of 47 Humana PA cases submitted with this bundle by clinicians affiliated with the HealthRX network between January and June 2025, 31 received approval on the first submission (66 percent first-pass approval rate), compared with a reported industry first-pass rate of approximately 20 percent for PCSK9 inhibitors. These figures are preliminary and drawn from a small convenience sample; they should not be generalized until prospective validation is complete.

Formulary Tier and Out-of-Pocket Cost on Humana Plans

On Humana commercial plans, alirocumab typically lands on tier 4 (specialty, preferred) or tier 5 (specialty, non-preferred). Tier 4 coinsurance commonly runs 25 to 30 percent after the deductible; tier 5 commonly runs 30 to 40 percent. For a $580 list-price drug, a 30 percent coinsurance represents $174 per month ($2,088 per year) before any copay accumulation toward the out-of-pocket maximum.

On Humana Medicare Advantage Part D plans, specialty tier cost-sharing in 2025 is typically 25 to 33 percent coinsurance during the initial coverage phase. After the 2025 Medicare Prescription Payment Plan restructuring, out-of-pocket costs for Part D specialty drugs are capped at $2,000 annually beginning January 1, 2025, under the Inflation Reduction Act provisions [4].

Patients who reach the catastrophic coverage phase pay $0 coinsurance on Part D drugs, a change effective January 2024. This means the financial burden for Medicare Advantage members who persist through the coverage phases may be substantially lower in 2025 than in prior years.

Manufacturer Savings Programs and Patient Assistance

Sanofi and Regeneron offer the Praluent Savings Card for commercially insured patients. The program may reduce monthly cost-sharing to as low as $0 per month for eligible patients, subject to program terms and an annual cap. The card cannot be used by patients enrolled in Medicare, Medicaid, or any federal or state government health program. Full program details and eligibility criteria are maintained by the manufacturer; patients should verify current terms directly with Sanofi.

For uninsured or underinsured patients, the Sanofi Patient Assistance Program (PAP) provides Praluent at no cost to qualifying patients below specific income thresholds. Applications require proof of income and insurance status and are reviewed by Sanofi's patient-services team. The NeedyMeds database and RxAssist.org maintain updated links to the PAP application for reference.

Patients transitioning from commercial insurance to Medicare should be counseled that the copay card will no longer apply after Medicare enrollment. Clinicians should address this transition point proactively to prevent a gap in therapy for high-risk ASCVD patients whose clinical indication remains active.

Does Humana Cover Praluent for Weight Loss?

No. Alirocumab has no FDA-approved indication for weight loss and no evidence base supporting its use for obesity management. The drug's mechanism, PCSK9 inhibition, targets hepatic LDL receptor recycling, not adipose tissue metabolism or satiety pathways. Humana, in line with all other U.S. payers, will not authorize alirocumab for a weight-loss indication regardless of plan type. Patients seeking coverage for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for obesity management must pursue separate coverage pathways specific to those agents [11].

CMS prohibits Medicare Advantage and Part D plans from covering drugs approved solely for anorexia, weight loss, or weight gain under 42 CFR 423.100, but alirocumab is not in that excluded category; it is excluded from weight-loss coverage simply because it is not indicated for that use [4].

Monitoring and Dose Adjustments That Affect Ongoing Authorization

Alirocumab is initiated at 75 mg subcutaneously every two weeks. If LDL-C response is insufficient (LDL remains above 70 mg/dL for ASCVD patients at 8 to 12 weeks), the dose may be titrated to 150 mg every two weeks. The alternative dosing regimen, 300 mg subcutaneously every four weeks (monthly), is also FDA-approved and may improve adherence for patients who prefer monthly injections [1].

Humana reauthorization typically requires a follow-up lipid panel demonstrating LDL-C response to alirocumab. A 50 percent or greater LDL reduction from baseline, or an LDL-C below 70 mg/dL for ASCVD patients, generally satisfies the ongoing medical-necessity standard. If LDL-C is paradoxically low on alirocumab (below 25 mg/dL), the ACC/AHA 2022 Guideline on Cardiovascular Prevention notes that current evidence does not require dose reduction on that basis alone, but the finding should be communicated to the insurer during reauthorization [12].

Thyroid function tests and hepatic enzyme panels are not required for routine alirocumab monitoring, which distinguishes it from statin therapy, where annual CK and liver enzyme surveillance is sometimes requested by payers. The FDA label does not mandate routine laboratory monitoring beyond the lipid panel [1].

Special Populations: FH Patients and Pediatric Considerations

The FDA extended the alirocumab approval to include patients aged 8 years and older with HeFH in 2021, based on the ODYSSEY KIDS trial, which demonstrated significant LDL-C reductions in pediatric patients [13]. Humana commercial plans may cover the pediatric indication, but PA criteria for patients under 18 are frequently more complex and may require documentation from a pediatric lipidologist.

Homozygous FH (HoFH) represents the most severe form of the condition, with LDL-C levels often exceeding 300 to 500 mg/dL from childhood. In HoFH, residual LDLR activity determines alirocumab response; patients with null/null LDLR mutations may derive limited benefit from PCSK9 inhibition because there are no functional receptors for the drug to upregulate. Lomitapide (Juxtapid) or evinacumab (Evkeeza) are alternative agents for HoFH that Humana reviews under separate PA criteria [14].

Pregnancy is listed as a precaution in the alirocumab label. Statin therapy should be discontinued before conception or upon pregnancy confirmation. Alirocumab's role in pregnancy is not established; Humana and other payers will not authorize it for pregnant patients outside a documented clinical trial.

Key Differences: Alirocumab vs. Evolocumab on Humana Formularies

Both alirocumab (Praluent) and evolocumab (Repatha) are PCSK9 inhibitors with similar mechanisms, LDL-lowering efficacy, and approved indications. On some Humana plans, one agent may be preferred over the other based on negotiated rebates; patients who receive a denial for alirocumab should ask whether evolocumab is on the preferred formulary. Switching from a non-preferred to a preferred PCSK9 inhibitor sometimes eliminates the prior-authorization barrier or reduces tier cost-sharing without sacrificing efficacy.

The FOURIER trial (N=27,564) evaluated evolocumab in stable ASCVD patients and demonstrated a 15 percent reduction in the primary MACE composite at 2.2 years (HR 0.85; P<0.001), a result nearly identical in magnitude to ODYSSEY OUTCOMES [15]. Either trial can be cited in a letter of medical necessity when the plan's preferred agent differs from the one prescribed.

If evolocumab is preferred and the prescriber has a clinical reason to use alirocumab specifically (for example, the monthly 300 mg dosing schedule for adherence, or patient history with the every-two-week regimen), that rationale should be documented explicitly in the PA submission.